Khanh Tu

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Manish R. Patel, Todd M. Bauer, Antonio Jimeno et al. · Journal of Clinical Oncology · 2020 · 69 citations

Medicine, Oncology, Pharmacology +16

Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).

Neeta Somaiah, Sant P. Chawla, Matthew S. Block et al. · Journal of Clinical Oncology · 2017 · 20 citations

Medicine, Immunology, Oncology +17

Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).

Giovanna Speranza, Robert J. Kinders, Sonny Khin et al. · Journal of Clinical Oncology · 2012 · 19 citations

Medicine, Pharmacology, Pharmacotherapy +15

Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.

Nehal J. Lakhani, Martin Gutierrez, Linda Duska et al. · Journal of Clinical Oncology · 2021 · 16 citations

Medicine, Oncology, Pharmacology +9

Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.

Geraldine O’Sullivan Coyne, Khanh Tu, Shivaani Kummar et al. · Journal of Clinical Oncology · 2018 · 12 citations

Life Sciences, Molecular Biology, Oncology +16